SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of hematopoietic and solid malignancies.

The company was founded in 2010 as a spin-off of the Department of Immunology at the University of Tübingen.

Our goal is to enhance the therapeutic efficacy of antibody treatment by improving the selective activation of immune effector cells, and to bridge the “translational gap” between conception and clinical evaluation as fast as possible.

To this end, SYNIMMUNE GmbH is establishing its own GMP-compliant production unit and works in close co-operation with the University Hospital in Tübingen, Germany.